Alert Indications, Safety, and Warnings

Reveal LINQ™ Insertable Cardiac Monitor

The Reveal LINQ insertable cardiac monitor (ICM) is a wireless and powerfully small insertable cardiac monitor ideal for patients experiencing infrequent symptoms that require long-term monitoring or ongoing management.

Download Brochure
Close-up view of the front side of the Reveal LINQ insertable cardiac monitor
Alert Indications, Safety, and Warnings

Overview

The World's Smallest, Most Accurate Insertable Cardiac Monitor1,2

The Reveal LINQ ICM system provides innovative ways to allow you to focus on what matters most — patient care.

Product Features

Powerfully Small and Simple

  • The Reveal LINQ ICM is one-third the size of a AAA battery (1.2 cc).
  • It has a minimally invasive, simplified insertion procedure.
  • The device is 1.5T and 3T MRI conditional.*

*Reveal LINQ has demonstrated to pose no known hazards in a specified MRI environment with specified conditions of use. Please see the Reveal LINQ MRI Technical Manual for more details.

Proven ICM Technology

  • TruRhythm™ Detection inside Reveal LINQ ICM features the world's most accurate AF detection algorithm.2
  • 900+ published clinical articles and abstracts for the Reveal™ family of ICMs.3

View the ICM Insertion Procedure Animation

Patient Monitoring Solutions

Exclusive Services and Solutions

Horizontal diagram that shows the exclusive services and solutions that correspond with the Reveal LINQ ICM

1. Streamline Device Programming and Interrogation

Reveal LINQ Mobile Manager
A single, app-based solution for managing:

  • Device registration, activation, and CareLink™ pre-enrollment
  • Guided workflow animations
  • Integrated patient education
Discover More

2. World's Smallest, Most Accurate ICM1,2

Reveal LINQ ICM with TruRhythm Detection
The Reveal LINQ ICM is part of the exclusive services and solutions designed to get you back to caring for patients.

3. Direct Support for Patient Monitor Connectivity Issues

Medtronic Stay Connected Service
A specialized patient service for monitor troubleshooting, connectivity issues, and other questions:

Direct patient line for fast service (1-866-470-7709)

7 a.m.–7 p.m. CT, Monday–Friday

4. Customize Alerts for Clinically Actionable Reports

CareLink Network
A remote monitoring network that enables data-driven care decisions:

  • CareAlert™ notifications allow for customized reports by clinic and/or individual patient
  • Cardiac Compass™ report provides a 90-day view of patient cardiac data
View Details

Monitoring Data

Long-term Monitoring for Better Patient Outcomes

The Reveal LINQ ICM continuously monitors patients for up to 3 years.‡ Learn more about long-term heart monitoring for suspected AF, syncope, and cryptogenic stroke.

 

30 Days Is Not Enough

2 Years Is Not Enough

Superior Diagnostic Yield

Informed Treatment Decisions

Cryptogenic Stroke
(CRYSTAL-AF Study)§

 

88%

of patients who had AF would have been missed if only monitored for 30 days ll4

30%

of cryptogenic stroke AF diagnoses occur between years 2 and 34

8.8x

more AF detected at 36 months with ICM vs. conventional follow-up¶4

97%

of patients in whom AF was detected received oral anticoagulants at 12 months4

Syncope

ICM recommended for syncopal episodes
> 30 days apart5

20%

of syncope diagnoses occur between years 2 and 37

3.6x

more likely to reach a syncope diagnosis with ICM vs. conventional care#8

82%

of Reveal ICM guided diagnoses led to treatment10

Suspected AF (REVEAL AF Study)**

84.5%

of patients with AF would have been missed if only monitored for 30 days6

16%

of patients with ICM-detected AF would be missed if monitoring stopped at 2 years6

4.3x

more likely to reach a diagnosis with ICM in 12 months vs. one-time, 30-day monitor9

76%

of patients with ICM-detected AF had a change in clinical management6

‡Reference the Reveal LINQ ICM Clinician Manual for usage parameters.
§The CRYSTAL-AF Study was a randomized, controlled study conducted on 441 patients to assess whether long-term monitoring with Reveal XT is more effective than conventional follow-up (control) for detecting atrial fibrillation in patients with cryptogenic stroke.
llBased on Kaplan-Meier estimates.
In the CRYSTAL-AF study, the control group included 88 conventional ECGs, 20 24-hour Holters, and 1 event recorder.
#2018 ESC Guidelines for Diagnosis and Management of Syncope defined conventional testing as undefined physician discretion for monitoring excluding ICM, External Loop Recorder, Tilt Test, EP Study, Recurrent 12-lead ECG, or 7-day Holter monitor.
**The REVEAL AF Study was a prospective, single-arm, multicenter study to quantify the incidence of AF in patients at high risk for but without previously known AF using an ICM (Reveal LINQ or Reveal XT).

Advanced Detection Algorithms

Unmatched Accuracy

Reduce false episode review burden while maintaining high sensitivity.11

Discover more about the device innovations that provide leading detection accuracy.

Industry-leading TruRhythm Algorithms

Our TruRhythm detection algorithms streamline episodes without sacrificing sensitivity.

Small box with the words bradycardia and pause detection on blue backgrounds

Smart Filtering

Second sensing filter analyzes rhythms for possible undersensing in bradycardia and pause detection.

Small navy blue box with the letters AF inside

Self-learning

AF algorithm learns and adapts to patients with sinus arrhythmia.

pdf TruRhythm Detection Technical Overview (.pdf)

View the PDF to learn more about TruRhythm detection inside the Reveal LINQ insertable cardiac monitor.

287KB

Superior Accuracy in AF Detection

Experience fewer false alerts11 with the Reveal LINQ ICM with TruRhythm Detection.

Lowest Published Rate of  AF False Episodes††11-14

4.7%

AF False Positive Rate††11

Chart demonstrating that the Reveal LINQ ICM has the lowest published rate of AF false episodes

Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done.

††Based on AF episodes ≥ 2 minutes and in known AF patients. % of false positives = (1 – episode PPV). AF episodes PPV may vary between gross and patient average.
‡‡Lux-Dx™ ICM, Confirm Rx™ with SharpSense™ technology, and BIOMONITOR™ III have no published clinical evidence showing AF episode PPV or AF sensitivity.

TruRhythm Global Grand Rounds Webinar

An electrophysiologist, a device nurse, and a Medtronic scientist discuss the TruRhythm algorithms and their impact from an EP and nurse perspective.

Log in and View

Model Specifications

pdf Reveal LINQ ICM Specifications (.pdf)

Download the specifications sheet for details on the Reveal LINQ insertable cardiac monitor.

2.1MB

Indications

The Reveal LINQ Insertable Cardiac Monitor is an implantable patient-activated and automatically activated monitoring system that records subcutaneous ECG and is indicated in the following cases:

  • Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
  • Patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain, which may suggest a cardiac arrhythmia

This device has not been specifically tested for pediatric use.

Additional Resources

Manuals and Technical Guides

Access prescriber, implant, MRI, and other manuals on the Medtronic Manual Library. Search by the product name (Reveal LINQ) or model number (LNQ11). You may also call 800-961-9055 for a copy of a manual.

Product manuals

Access product manuals from the Medtronic Manual Library by searching for the product name or model number.

Visit Library

References

1

ICM Size Comparison Guide. Medtronic data on file. 2021. 

2

ICM Accuracy Comparison Guide. Medtronic data on file. 2021.

3

Medtronic Reveal™ Publications. Medtronic data on file. 2021.

4

Sanna T, Diener H-C, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. June 26, 2014;370(26):2478-2486.

5

Writing Committee Members, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Heart Rhythm. September 2019;16(9):e227-e279.

6

Reiffel JA, Verma A, Kowey PR, et al. Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study. JAMA Cardiol. October 1, 2017;2(10):1120-1127.

7

Furukawa T, Maggi R, Bertolone C, Fontana D, Brignole M. Additional diagnostic value of very prolonged observation by implantable loop recorder in patients with unexplained syncope. J Cardiovasc Electrophysiol. January 2012;23(1):67-71.

8

Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. June 1, 2018;39(21):1883-1948.

9

Reiffel JA, Verma A, Kowey PR, et al. Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. Am Heart J. January 2020;219:128-136.

10

Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace. February 2011;13(2):262-269.

11

Pürerfellner H, Sanders P, Sarkar S, et al. Adapting detection sensitivity based on evidence of irregular sinus arrhythmia to improve atrial fibrillation detection in insertable cardiac monitors. Europace. November 2018;20(FI_3):f321-f328.

12

Confirm Rx™ ICM DM3500 FDA Clearance Letter. 2017.

13

Nölker G, Mayer J, Boldt L-H, et al. Performance of an Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. J Cardiovasc Electrophysiol. December 2016;27(12):1403-1410.

14

BIOTRONIK BioMonitor™ 2 Technical Manual. 2017.